Current antiviral drugs only target one virus: one drug against one virus
OUR BUSINESS IS ANTIVIRALS; OUR APPROACH IS DIFFERENT
The Challenge – Hundreds of viral infections have no cure. Traditional antiviral therapies and vaccines are developed to target one virus at a time; and this limitation is compounded by the fact that few antiviral drugs are able to defend against a virus’s ability to quickly develop drug-resistance.
Broad Spectrum Antivirals – Evrys Bio’s approach to antiviral therapy is different. Uniquely, Evrys Bio antivirals target special human proteins, known as sirtuins, enhancing their natural ability to fight powerful infections. Because the function of sirtuins is essential for different viruses, Evrys Bio antivirals address many, if not all, of the viruses that cause a given infectious disease. For example, our vision is that an Evrys Bio product will address hepatitis caused by hepatitis B virus and hepatitis C virus. Current products only address one or the other, not both. Furthermore, because sirtuins are the patient’s own proteins, viruses cannot rapidly develop drug-resistance against sirtuin-targeted drugs, completely transforming the way we treat and cure viral infections today.
Actualizing Innovation. A proven team advancing today’s innovation into tomorrow’s transformative therapeutics.
Platform & Pipeline
Next Gen Antivirals that engage the patient’s own immunity to naturally defend against viral infection without the emergence of drug resistance.
Transformative Achievements. Evrys Bio in the News.